Clinical Trial Update: A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension [Phase 3]

View source ↗

Summary

This update reports the completion and posted results of a Phase 3 pharmacokinetic study of azilsartan medoxomil (TAK-536) in pediatric patients aged 6 to under…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Azilsartan medoxomil (azilsartan medoxomil)

Snippet

Sponsor: Takeda | Conditions: Pediatric Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2016-04-07